Logistical challenges of CAR T-cell therapy in non-Hodgkin lymphoma: a survey of healthcare professionals

被引:0
作者
Sureda, Anna [1 ]
Adam, Shiraz El [2 ]
Yang, Shibing [3 ]
Griffin, Evelyn [2 ]
Baker, Jenny [2 ]
Johnston, Karissa [2 ]
Navarro, Fernando Rivas [3 ]
Alhasani, Sarah [3 ]
Chhibber, Anindit [3 ]
Wang, Anthony [4 ]
Mutebi, Alex [3 ]
机构
[1] Univ Barcelona, Hosp Duran i Reynals, IDIBELL, Inst Catala Oncol, Barcelona, Spain
[2] Broadstreet HEOR, Vancouver, BC, Canada
[3] Genmab US Inc, Plainsboro, NJ 08536 USA
[4] AbbVie Inc, N Chicago, IL USA
关键词
access to care; CAR T cell therapy; clinical decision-making; logistical challenges; non-Hodgkin lymphoma;
D O I
10.1080/14796694.2024.2393566
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: Characterize the logistical challenges faced by healthcare professionals (HCPs), patients and caregivers during the chimeric antigen receptor T-cell (CAR T) treatment process for non-Hodgkin lymphoma patients. Materials & methods: HCPs in the US and UK experienced with CAR T administration participated in interviews and completed a web-based survey. Results: A total of 133 (80 US, 53 UK) HCPs participated. Two or more logistical challenges were identified by >= 60% of respondents across all stages of the CAR T process. Commonly reported challenges were lengthy waiting periods, administrative and payer-related barriers, limited healthcare capacity, caregiver support and (particularly in the US) patient out-of-pocket costs. Conclusion: The CAR T treatment process presents numerous challenges, highlighting an unmet need for more convenient therapies. PLAIN LANGUAGE SUMMARY Chimeric antigen receptor T-cell (CAR T) therapy is a new treatment for patients with non-Hodgkin lymphoma that have not responded to other types of treatment. CAR T therapy uses a person's own immune cells (T cells), which are modified in a laboratory to attack cancer cells. While CAR T therapy has the potential to be effective, there are challenges associated with the treatment process. In this study, we surveyed 133 healthcare professionals (HCPs) in the United States and United Kingdom to understand their experiences with logistical challenges involved in navigating the CAR T process. More than 60% of participants identified two or more logistical challenges at every stage of the CAR T treatment process. The most commonly reported challenges included long waiting periods, limited room at hospitals, availability of caregivers to support patients and issues related to out-of-pocket costs, travel and lodging for patients who are treated at specialized centers. In the United States, challenges related to insurance coverage and out-of-pocket costs for patients were highlighted. More than half of HCPs reported that patients' cancer getting worse while waiting to receive CAR T was a reason why patients may not proceed to treatment. While operational improvements might address some challenges in the CAR T treatment process, these findings highlight the need for more convenient, readily available and easily administered therapies for patients with non-Hodgkin lymphoma.
引用
收藏
页码:2855 / 2868
页数:14
相关论文
共 23 条
  • [1] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
    Abramson, Jeremy S.
    Palomba, M. Lia
    Gordon, Leo I.
    Lunning, Matthew A.
    Wang, Michael
    Arnason, Jon
    Mehta, Amitkumar
    Purev, Enkhtsetseg
    Maloney, David G.
    Andreadis, Charalambos
    Sehgal, Alison
    Solomon, Scott R.
    Ghosh, Nilanjan
    Albertson, Tina M.
    Garcia, Jacob
    Kostic, Ana
    Mallaney, Mary
    Ogasawara, Ken
    Newhall, Kathryn
    Kim, Yeonhee
    Li, Daniel
    Siddiqi, Tanya
    [J]. LANCET, 2020, 396 (10254) : 839 - 852
  • [2] Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis
    Al-Mansour, Mubarak
    Al-Foheidi, Meteb
    Ibrahim, Ezzeldin
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2020, 13 (04) : 1 - 14
  • [3] Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy
    Barata, Anna
    Hoogland, Aasha I.
    Hyland, Kelly A.
    Otto, Amy K.
    Kommalapati, Anuhya
    Jayani, Reena V.
    Irizarry-Arroyo, Nathaly
    Collier, Aaron
    Rodriguez, Yvelise
    Welniak, Taylor L.
    Booth-Jones, Margaret
    Logue, Jennifer
    Small, Brent J.
    Jain, Michael D.
    Reblin, Maija
    Locke, Frederick L.
    Jim, Heather S. L.
    [J]. PSYCHO-ONCOLOGY, 2021, 30 (08) : 1294 - 1301
  • [4] CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion
    Boeri, Marco
    Purdum, Anna G.
    Sutphin, Jessie
    Hauber, Brett
    Kaye, James A.
    [J]. FUTURE ONCOLOGY, 2021, 17 (34) : 4697 - 4709
  • [5] Borgert R, 2021, AM J MANAG CARE, V27, pS253, DOI 10.37765/ajmc.2021.88737
  • [6] One size fits all? What counts as quality practice in (reflexive) thematic analysis?
    Braun, Virginia
    Clarke, Victoria
    [J]. QUALITATIVE RESEARCH IN PSYCHOLOGY, 2021, 18 (03) : 328 - 352
  • [7] Cliff ERS., 2023, AM SOC CLIN ONCOL ED, V43, DOI 10.1200/EDBK397912
  • [8] Directory of CAR T-cell therapy centers, 2023, BLOOD MARROW TRANSPL
  • [9] Ellis Kristina, 2021, Healthc Policy, V16, P89, DOI 10.12927/hcpol.2021.26430
  • [10] Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
    Fowler, Nathan Hale
    Dickinson, Michael
    Dreyling, Martin
    Martinez-Lopez, Joaquin
    Kolstad, Arne
    Butler, Jason
    Ghosh, Monalisa
    Popplewell, Leslie
    Chavez, Julio C.
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter A.
    Ho, P. Joy
    Perez-Simon, Jose Antonio
    Chen, Andy, I
    Nastoupil, Loretta J.
    von Tresckow, Bastian
    Ferreri, Andres Jose Maria
    Teshima, Takanori
    Patten, Piers E. M.
    McGuirk, Joseph P.
    Petzer, Andreas L.
    Offner, Fritz
    Viardot, Andreas
    Zinzani, Pier Luigi
    Malladi, Ram
    Zia, Aiesha
    Awasthi, Rakesh
    Masood, Aisha
    Anak, Oezlem
    Schuster, Stephen J.
    Thieblemont, Catherine
    [J]. NATURE MEDICINE, 2022, 28 (02) : 325 - +